How much cash does MapLight Therapeutics, Inc. generate?

MapLight Therapeutics, Inc. (MPLT) generated -$145.0M in operating cash flow over the trailing twelve months.

Where does MapLight Therapeutics, Inc. 's cash flow data come from?

Every line is extracted from MapLight Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

MapLight Therapeutics, Inc. MPLT Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$199.48M-23.8%	-$161.15M-56.7%	-$102.83M-11.3%	-$92.43M-14.1%	-$80.99M-4.4%
Depreciation and amortization	$574K-0.7%	$578K-8.5%	$632K-13.7%	$732K—	——
Stock-based compensation	——	——	——	——	——
Gain (loss) on sale of assets	-$9.25K-32.1%	-$7K+65.0%	-$20K+39.4%	-$33K+28.3%	-$46K+22.0%
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	——	——	——	——	——
Change in other assets	——	——	——	——	——
Change in operating lease liabilities	——	——	——	——	——
Net cash from operating activities	——	——	——	——	——
Capital expenditures	——	——	——	——	——
Purchases of investments	——	——	——	——	——
Proceeds from maturities/sales of investments	——	——	——	——	——
Net cash from investing activities	——	——	——	——	-$23.09M+71.4%
Taxes paid for net share settlement	——	——	——	——	——
Payment of debt issuance costs	——	——	——	——	——
Proceeds from issuance of preferred stock	——	$198.84M—	——	——	——
Net cash from financing activities	——	——	——	——	——
Net increase (decrease) in cash	——	——	——	——	-$19.25M+53.7%
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——	——
Depreciation	$574K-0.7%	$578K-8.5%	$632K-13.7%	$732K—	——
Equity Method Investment, Realized Gain (Loss) on Disposal	——	——	——	——	——
Operating lease liabilities	——	——	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Noncash Lease Expense	——	——	——	——	——
Proceeds from disposition of marketable securities and other investments	——	——	——	——	——
Proceeds From Exercises Of Stock Options And Employee Stock Purchase Plan Issuances	——	——	——	——	——
Proceeds From Initial Public Offering Of Common Stock And Private Placement Net Of Underwriting Fees	——	$275.72M—	——	——	——
Exchange Offer (Note 12)	——	$507.66M—	——	——	——
Increase Decrease In Operating Lease Liability	——	——	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	——
Deferred Financing Costs Included In Accounts Payable And Accrued Expenses	——	——	——	——	——
Purchase Of Property And Equipment Included In Accounts Payable And Accrued Expenses	——	——	——	——	——
Free cash flow	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does MapLight Therapeutics, Inc. generate?: MapLight Therapeutics, Inc. (MPLT) generated -$145.0M in operating cash flow over the trailing twelve months.
Where does MapLight Therapeutics, Inc. 's cash flow data come from?: Every line is extracted from MapLight Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.